Hydroxychloroquine Reduces COVID-19 Morbidity and Mortality: Statistical Evidence from a Cross-Country Study

Hydroxychloroquine reduces COVID-19 morbidity and mortality: statistical evidence from a cross-country study – Doctors for COVID Ethics (doctors4covidethics.org)

“According to a recent news story, ‘scientists are mystified’ about the low numbers of COVID-19 cases and deaths in African countries: ‘Africa doesn’t have the vaccines and the resources to fight COVID-19 that they have in Europe and the U.S., but somehow they seem to be doing better.’

Interestingly, aside from confirming yet again that the vaccines don’t work, the African data also provide evidence supporting the efficacy of hydroxychloroquine. A new study by economists Hideki Toya and Mark Skidmore, which carefully controlled for other plausible contributing factors such as age distribution, healthcare capacity, and sunlight (exposure to which increases vitamin D levels), shows a convincing protective effect of hydroxychloroquine. While this is primarily an antimalarial drug, its antiviral properties have long been recognized. The same is true of ivermectin, which shows compelling activity against SARS-CoV-2 in vitro and also in vivo.

Note that the morbidity and mortality data analyzed by Toya and Skidmore are are unaffected by vaccination rates, since they are from early 2020. You can read their study here: https://mark-skidmore.com/2021/11/22/scientists-mystified-wary-as-africa-avoids-covid-disaster/.”

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: